Tivicay is a brand-name medication that contains dolutegravir as its active ingredient. It belongs to the therapeutic class of HIV management drugs and is available in a 50 mg tablet form. In Hong Kong, Tivicay is a prescription-only product approved for the treatment of HIV-1 infection. The medication is manufactured by ViiV Healthcare and marketed under the Tivicay name worldwide.
Dolutegravir is an integrase strand transfer inhibitor (INSTI). It blocks the HIV-1 integrase enzyme, which is required for the virus to insert its genetic material into the host cell’s DNA. By preventing this step, dolutegravir stops the replication cycle of HIV, leading to reduced viral load and preservation of the immune system.
Key pharmacologic points:
Tivicay is approved in Hong Kong (and internationally) for the following indications:
The medication may be used as part of a single-tablet regimen (e.g., with abacavir/lamivudine) or as a separate component of a combination therapy, depending on the prescriber’s plan.
Disclaimer: Off-label use requires medical supervision, thorough risk assessment, and adherence to local clinical guidelines.
This article provides educational information about Tivicay and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Tivicay is commonly combined with two nucleoside reverse transcriptase inhibitors (NRTIs) as part of a recommended triple-therapy regimen. Compatibility depends on the specific NRTIs and any co-existing medications; the prescribing clinician will select a suitable combination.
Insomnia is a reported side effect that often improves with time. Patients can try taking the tablet earlier in the day or discuss sleep-aid options with their healthcare provider if the problem persists.
Dolutegravir does not require dose modification for mild-to-moderate renal impairment. In severe renal dysfunction, clinical judgment is required, and the prescriber may monitor drug levels or consider alternative regimens.
While a bathroom cabinet is convenient, it may experience higher humidity. It is best to keep the tablets in a cool, dry place at room temperature, such as a drawer or pantry, away from moisture.
Both are potent integrase inhibitors, but dolutegravir has a longer half-life, allowing once-daily dosing without a boosting agent. Elvitegravir often requires co-administration with a pharmacokinetic booster (cobicistat).
Carry the medication in its original packaging with a copy of the prescription. Keep it in hand luggage to avoid temperature extremes and ensure you have enough tablets for the entire trip plus a few extra days.
Antacids containing aluminum, magnesium, or calcium can lower dolutegravir absorption. To minimize this effect, take Tivicay at least 2 hours before or after the antacid.
Dolutegravir does not diminish the efficacy of hormonal contraceptives. However, patients should discuss all contraceptive options with their provider, especially when other interacting drugs are present.
Transitioning between integrase inhibitors generally does not require a washout period, but the switch should be overseen by a clinician to ensure continuous viral suppression.
Dolutegravir is not a prohibited substance in most athletic doping programs and is not typically screened for in routine drug tests. Athletes should still disclose all medications to anti-doping authorities.
